Please wait while the formulary information is being retrieved.
ETHYOL (AMIFOSTINE CRYSTALLINE)
- Prevention of chemotherapy-induced renal impairment
- Prevention of xerostomia secondary to radiation therapy
- Ethyol Iv Solution
- Ethyol Intravenous Solution
- Amifostine Crystalline Iv Solution
- Amifostine Crystalline Intravenous Solution
- By Indication
500 mg intravenous solution
- Dosage information is not available
500 mg intravenous solution
- Dosage information is not available
500 mg intravenous solution
- Dosage information is not available
crystalline 500 mg intravenous solution
- Dosage information is not available
Prevention of chemotherapy-induced renal impairment
- Infuse 910 mg/m2 over 15 minute(s) by intravenous route once daily
- Infuse 740 mg/m2 over 15 minute(s) by intravenous route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Dehydration
- Hypotension
- Hypovolemia
- Lactating mother
Contraindicated
- Hypocalcemia
- Vomiting
Severe
Moderate
- Cardiac arrhythmia
- Cerebrovascular accident
- Chronic heart failure
- Myocardial ischemia
- Transient cerebral ischemia
ETHYOL (AMIFOSTINE CRYSTALLINE)
- Prevention of chemotherapy-induced renal impairment
- Prevention of xerostomia secondary to radiation therapy
- Hypotension
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute respiratory insufficiency
- Anaphylaxis
- Apnea
- Atrial fibrillation
- Atrial flutter
- Bradycardia
- Cardiac arrest
- DRESS syndrome
- Dyspnea
- Erythema multiforme
- Exfoliative dermatitis
- Extrasystoles
- Hypertension
- Hypocalcemia
- Hypoxia
- Laryngeal edema
- Palmar rash
- Renal failure
- Seizure disorder
- Stevens-johnson syndrome
- Supraventricular tachycardia
- Tachycardia
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Allergic dermatitis
- Blurred vision
- Chest pain
- Chills
- Diplopia
- Dizziness
- Drowsy
- Fever
- Flushing
- Hiccups
- Injection site sequelae
- Malaise
- Pruritus of skin
- Skin rash
- Sneezing
- Syncope
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Amifostine
Not recommended by manufacturer. Safety and efficacy not established.
- 1 Day – 18 Years
- Not recommended by manufacturer. Safety and efficacy not established.
Amifostine
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
Amifostine
Mfr recommends breastfeeding be discontinued if treated with amifostine
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends breastfeeding be discontinued if treated with amifostine |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool